<SEC-DOCUMENT>0001193125-17-307560.txt : 20171011
<SEC-HEADER>0001193125-17-307560.hdr.sgml : 20171011
<ACCEPTANCE-DATETIME>20171011080034
ACCESSION NUMBER:		0001193125-17-307560
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171010
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171011
DATE AS OF CHANGE:		20171011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		171131768

	BUSINESS ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 301
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
		BUSINESS PHONE:		818-661-5000

	MAIL ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 301
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d469645d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;10, 2017 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MannKind Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-50865</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">13-3607736</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>30930 Russell Ranch Road, Suite 301</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Westlake Village, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>91362</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:
<FONT STYLE="white-space:nowrap">(818)&nbsp;661-5000</FONT> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;is</FONT> intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions (see General Instruction A.2. of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12&nbsp;under</FONT> the Exchange Act (17 <FONT STYLE="white-space:nowrap">CFR&nbsp;240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement&nbsp;communications</FONT> pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17
<FONT STYLE="white-space:nowrap">CFR&nbsp;240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement&nbsp;communications</FONT> pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17
<FONT STYLE="white-space:nowrap">CFR&nbsp;240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (&#167;
<FONT STYLE="white-space:nowrap">240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02. Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2017, we issued a press release announcing certain estimated financial results as of and for the three months ended September&nbsp;30,
2017, in addition to a registered direct offering of our common stock.&nbsp;The financial results included in the press release are preliminary and unaudited and may differ from what will be reflected in our condensed financial statements as of and
for the three months ended September&nbsp;30, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated October&nbsp;10, 2017</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d469645dex991.htm">Press Release dated October&nbsp;10, 2017 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MANNKIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;11, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Thomson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Thomson, Ph.D., J.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President, General Counsel and Secretary</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d469645dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g469645man.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MannKind Announces $61 Million Registered Direct Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WESTLAKE VILLAGE, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) &#151; MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) today announced that it entered into
definitive agreements with certain institutional investors and other investors in connection with a registered direct offering of an aggregate of 10,166,600 shares of common stock at an offering price of $6.00 per share, for gross proceeds of
approximately $61&nbsp;million. The offering is expected to close on or about October&nbsp;13, 2017, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With this offering, we have made substantial progress in our efforts to recapitalize the company,&#148; said Michael Castagna, Chief Executive Officer
of MannKind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co. is acting as the exclusive placement agent for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After deducting the placement agent&#146;s fees, the net proceeds to MannKind are expected to be approximately $57.7&nbsp;million. MannKind intends to use the
net proceeds from the offering for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares are being offered pursuant to a shelf registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on April&nbsp;27, 2016. A final prospectus supplement related to the offering will be
filed with the SEC, and will be available on the SEC&#146;s website located at&nbsp;http://www.sec.gov&nbsp;and may also be obtained by contacting MannKind at 30930 Russell Ranch Road, Suite 301, Westlake Village, CA 91362, Attn: Investor Relations,
or by telephone at (818) <FONT STYLE="white-space:nowrap">661-5000;</FONT> or from the placement agent at H.C. Wainwright&nbsp;&amp; Co. LLC, 430 Park Avenue, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10022,
by calling (646) <FONT STYLE="white-space:nowrap">975-6996</FONT> or&nbsp;emailing <U>placements@hcwco.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although MannKind&#146;s financial results as of and for the three months ended September&nbsp;30, 2017 are not yet finalized, the following information
reflects its expectations with respect to such results based on currently available information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the three months ended September&nbsp;30, 2017, MannKind expects to report between $2.6&nbsp;million and $3.0&nbsp;million of gross Afrezza product revenue and between $1.8&nbsp;million and $2.2&nbsp;million of net
Afrezza product revenue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MannKind estimates that as of September&nbsp;30, 2017, its cash and cash equivalents were approximately $20.2&nbsp;million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MannKind estimates that as of September&nbsp;30, 2017, the principal balance outstanding for its 9.75% Senior Convertible Notes due 2019 and 8.75% Senior Convertible Notes due 2019 issued under its facility agreement
with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. was $60.0&nbsp;million; its 5.75% Convertible Senior Subordinated Exchange Notes Due 2018 was $27.7&nbsp;million; and its borrowings under the loan
arrangement with The Mann Group LLC was $79.7&nbsp;million. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MannKind estimates that the annual purchase requirements under the insulin supply agreement with Amphastar as of September&nbsp;30, 2017 were unchanged from June&nbsp;30, 2017, except for the impact of foreign currency
translation. MannKind has not yet purchased the annual minimum required quantities of insulin for 2017 of &#128;2.7&nbsp;million. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preliminary financial results presented above reflect MannKind&#146;s estimates based solely upon information available to it as of the date hereof, is not a comprehensive statement of its financial results or position as of or for the three months
ended September&nbsp;30, 2017, and has not been audited, reviewed or compiled by its independent registered public accounting firm, Deloitte&nbsp;&amp; Touche LLP. Accordingly, Deloitte&nbsp;&amp; Touche LLP does not express an opinion or any other
form of assurance with respect thereto. MannKind&#146;s actual third quarter results may differ materially from these estimates. Accordingly, investors should not place undue reliance upon these estimates. For example, during the course of the
preparation of the respective condensed consolidated quarterly financial statements and related notes thereto, additional items that would require material adjustments to be made to the estimated financial information presented above may be
identified. These estimates are not necessarily indicative of future performance or results of operations, and are not necessarily indicative of the results that may be expected for a full year. There can be no assurance that these estimates will be
realized, and estimates are subject to risks and uncertainties, many of which are not within our control. See &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements&#148; in MannKind&#146;s filings with the Securities
and Exchange Commission, including its most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> MannKind believes that its estimated quarterly financial
results presented above are consistent with the applicable trends and expectations discussed in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in its most recent quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MannKind </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such
as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (insulin human) inhalation powder, the Company&#146;s first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village,
California, and has a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the</FONT></FONT> art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit <U>www.mannkindcorp.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this press release that are not strictly historical in nature are forward-looking statements that involve risks and
uncertainties.&nbsp;These statements include, without limitation, statements regarding MannKind&#146;s expectations with respect to the completion, timing and size of its offering, the expected proceeds from the offering and its anticipated use of
the proceeds from the offering. Words such as &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;goal,&#148; &#147;potential&#148; and similar expressions are intended
to identify forward-looking statements. These forward-looking statements are based upon MannKind&#146;s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements
as a result of various risks and uncertainties, including, without limitation, risks associated with market conditions, the satisfaction of customary closing conditions related to the offering, MannKind&#146;s need and ability to raise additional
capital and other risks detailed in MannKind&#146;s filings with the SEC, including its </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2017. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect
events or circumstances after the date of this press release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rose Alinaya </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">818-661-5000</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@mannkindcorp.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g469645man.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g469645man.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $T!%0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?B0H))P!WH BMYC.OFKQ&?N^X]:;5M!)W)J0RCJEY+I]F]
MXD9ECA&Z6-1\Q0=2OJ1UQWIQ5W8F3Y5<L6EU!>VD5U;3++!,H>-U.0P/0T--
M.S&FFKHFI#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H QO$%T8X$ME.#+]X_[-;T8W=S*I*VAIN\=K:%SQ'&F>
M/0"L;7=C39'/'Q#=>9E8XPG]T@_SKJ]@K&'M6=!:SI=VJ3*/E<=#V]JY9)Q=
MC9.ZN>8?"S7O*US6?##/NMX)Y9;3_94.0RCVY!_.N_%TO<C4^\XL-4]YTSU:
MO/.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,# )]>1Z=17'"@G'VE1V1U2K-2Y(*[([#XBW$FG:Y%J&E?8]:TB!IGMB^5D
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MQ[>U>_A*'LH7>[/$Q-;VDK+9'<^ /A[+I^AG6+Q"-3N%S%$P_P!7'Z?[Q_\
MK>M<=?%7GRK8ZZ&&Y8\SW.FT^\:QNQ)SL/#K[5G4ASQ-8RY6=BC!U#*<@C((
MK@V.L=0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'GGQ;\3-HOAU=.MGVW>HY3(/*QC[Q_'('XFNW!4>>?,]D
M<>+J\D++=G#_  K\#_VU?#6M0BSIUJ_[I&'$T@_]E'\_QKLQN(Y%R1W.7"4.
M9\\MCWH5XQZQSVN:=L8WD*_*?]8!V]ZZ:-3[+,*D.J)_#]YOB:U<\Q\I]/2I
MK0L^8=*5U8VZP-@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /'_B_H%S>^(=$O26%E,4LY''2)B_!]LAC_ -\U
MZF"JJ,)1Z[GG8NFY3C+H>KV%C;Z98P65I$L5O @1$'8"O,E)R=V>A&*BK(LT
MAG.:KKUQ9ZS'IZVBR1.%!W=7R><?Y_*M8P35[F4IM2M8=I=F8M:G*9\F$E<_
M7H*TJ2O!7)A&TF=#7,;A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 0W5K!>VSV]S$LL+C#(XR#33:=T)I/1DH&
MT #M2&+0 A4$@D#(Z'TH 1(TC7"*%&<\>M ;#J "@ H * "@ H * "@ H *
F"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
